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Purpose: To report the effect of subthreshold transpupillary thermotherapy (TTT) in 
treating serous detachment of the neurosensory retina secondary to chronic central serous 
  chorioretinopathy (CCSC).
Methods: Seven eyes from five patients with CCSC, persistent serous detachment of the neuro-
sensory retina and a clinical course of between 12 and 60 months were treated. All eyes received 
large-spot TTT guided by indocyanine green angiography (ICGA). Subthreshold TTT was 
performed using an 810 nm diode laser with a spot size of 3.0 mm (power was set at 350 mW). 
Treatment was applied for 60 seconds to the areas of choroidal hyperfluorescence on ICGA.
Results: The mean number of TTT sessions was 1.4 ± 0.5. All eyes were followed up for at 
least 6 months (mean 9.6 ± 3.2 standard deviation; range 6–12 months). The mean logarithm of 
the minimum angle of resolution best-corrected visual acuity was significantly better   compared 
with baseline. All TTT-treated eyes had stable or improved vision (P , 0.001). Mean optical 
coherence tomography (OCT) central foveal thickness was significantly lower in all patients 
(P , 0.001) compared with pretreatment OCT, with a reduction in subretinal fluid and   resolution 
of serous detachment associated with anatomical fovea restoration. No patient had any treatment-
related side effects.
Conclusion: Modified subthreshold TTT appears to have a beneficial effect in treating patients 
with CCSC and persistent neurosensory detachment. The encouraging results and lack of   visually 
significant complications suggest that further investigation is warranted.
Keywords: central serous chorioretinopathy, indocyanine green angiography, neurosensory 
detachment, transpupillary thermotherapy
Introduction
Chronic central serous chorioretinopathy (CCSC) is a rare, severe disorder,   characterized 
by long-term persistence of subretinal exudation, extensive areas of retinal pigment 
epithelium (RPE) atrophy, cystoid macular edema, choroidal   neovascularization (CNV), 
and impairment of visual acuity (VA).1–5 Evidence is typically found of uneven 
and diffuse hyperfluorescence, often displaying multiple leaks with fluorescein 
  angiography (FA), and diffuse or multifocal areas of choroidal hyperfluorescence 
on indocyanine green angiography (ICGA).6 Long-term follow-up studies of patients 
with typical idiopathic CSC have demonstrated that patients with chronic, recurrent 
detachment and severe visual loss are part of the spectrum of CSC, although the precise 
pathogenesis remains obscure.7–9
There is still no established therapy for CCSC, and medical treatments have no 
proven influence on the course of the disease.10–12 Although selected cases of acute Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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CSC benefit from retinal laser photocoagulation,13,14 there 
is no standard treatment for CCSC. The area affected by 
the leakage in CCSC is often so diffuse that it requires 
extensive laser application, with subsequent development of 
bothersome scotomas. Anatomic improvements with some 
functional success in the treatment of CCSC have been 
observed for the use of photodynamic therapy (PDT) with 
verteporfin.15–17 The use of PDT in the treatment of chronic 
CCSC has not been without complication, and RPE atrophy 
and juxtafoveal CNV have been reported after PDT.18,19 Trans-
pupillary thermotherapy (TTT) has been advocated in the 
management of macular lesions, particularly in the treatment 
of CNV ,20 choroidal melanoma,21,22 choroidal hemangioma,23 
and CSC.24,25 The advantages of diode laser (810 nm) in the 
treatment of macular disease are related to low absorption by 
xanthophyll and poor absorption by   hemoglobin (allowing 
treatment through preretinal and   subretinal blood), with low 
energy delivery, thereby avoiding damaging photoreceptor 
cells.
In this small pilot study, we evaluate the use of ICGA-
guided large-spot subthreshold TTT in the management of 
serous macular detachment in the CCSC.
Methods
Seven eyes from five patients with chronic CCSC were 
  studied between February 2008 and January 2009. All patients 
  complained of visual disturbance, metamorphopsia, and 
  relative central scotomas. Their ocular   history was significant 
for periodic attacks of CSC, which left some subjective 
visual defects. CCSC was defined in patients with persistent 
serous macular detachment ($6 months’ duration; clinical 
course ranging between 1 and 5 years); associated RPE 
window defects and multiple leaks or leaks of undetermined 
source on FA; presence of choroidal hyperpermeability/
hyperfluorescence on ICGA; and neurosensory   detachment 
of the macula. Pretreatment VA ranged from 20/70 to 20/500. 
At baseline, all patients underwent ophthalmic examination 
including refraction, best-corrected visual acuity (BCVA) 
(Snellen chart), FA, ICGA, and optical coherence   tomography 
(OCT 3000, Humphrey Instruments, San Leandro, CA, USA). 
FA was performed to identify the presence of acute RPE leaks 
and areas of early or late   hyperfluorescence, indicating diffuse 
decompensation of the posterior blood–retina barrier or RPE 
atrophy. ICGA was used to identify areas of inner choroidal 
vascular   hyperpermeability, confirm the diagnosis, guide the 
TTT treatment, and rule out the   possibility that the choroidal 
new vessel could be masquerading as CSC. OCT, centered 
on the foveal region, was performed using the default setting 
of the crosshair mode, which scans 5.0 mm vertically and 
  horizontally. TTT with an 810 nm diode laser (Iris Medical 
OcuLight Slx, Iridex   Corporation,   Mountain, View, CA, USA) 
was delivered through a   dedicated   slit-lamp-mounted 
delivery system. A three-mirror   Goldmann lens was used 
with a   standard 3 mm spot in the laser slit lamp,   producing 
a   large-spot size of 3.24 mm in diameter on the retina. 
Treatment was applied at least 10 days after angiographic 
examination in all patients, with the same laser spot size and 
duration (3 mm; 60 seconds) in all patients (the power was 
set at 350 mW). Low-intensity TTT produces approximately 
60% lower energy levels than treatment with a 3 mm spot 
size and 800 mW setting. One or more   consecutive spots were 
applied to cover the area of choroidal hyperpermeability and 
diffuse leakage detected on ICGA. Only angiographic areas 
judged to be responsible for the macular detachment were 
selected for treatment. Treatment of the central macula was 
preferentially avoided.   Nonetheless,   treatment of the central 
area was performed if the foveal region was included in 
the affected zone. Visible retinal whitening was carefully 
avoided in view of subretinal exudation, shallow serous 
retinal detachment, presence of RPE anomalies (atrophy), and 
heavily pigmented fundus, which would also cause variations 
in temperature rise across the TTT field. All patients were 
scheduled for 1, 2, 3, and 6 months’ follow-up after TTT. 
A repeat TTT was   performed if angiographic dye leakage 
and OCT subretinal fluid persisted 3 months after treatment. 
The same treatment criteria as above were   followed for 
  retreatment. The study adhered to the tenets of the Declaration 
of Helsinki for research involving human subjects and was 
approved by the Ethics Committee. Written consent was 
obtained from all patients prior to treatment.
statistical analysis
Clinical data were analyzed to evaluate improvement in 
VA and the height of the foveal detachment after treatment. 
BCVA was converted to logarithm of the minimum angle of 
resolution (logMAR) for the analysis. Analysis of variance 
for repeated measures was performed. The level of statistical 
significance was set at P values lower than 0.05.
Results
Demographic data on the patients pretreatment and 
post-treatment are shown in Table 1. The patient ages 
at the time of therapy ranged from 55 years to 69 years 
(61.6 ± 5.6 years, mean ± standard deviation [SD]). 
There were three men and two women. All patients had 
a history of over 1 year (33.6 ± 17.7 months, mean ± SD; Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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range 12–60 months) of CCSC. The follow-up period ranged 
from 6 months to 12 months (9.6 ± 3.2 months, mean ± SD). 
Initial VA ranged from 0.04 to 0.3 (0.1 ± 0.08 logMAR, 
mean ± SD). Two patients had previously been treated with 
laser   photocoagulation for acute RPE leaks. FA showed RPE 
window defects (all patients had some degree of transmission 
hyperfluorescence corresponding to RPE atrophy involving 
the fovea in five eyes), and subfoveal leak was identified 
as the cause of the macular detachments in one eye. ICG 
angiography revealed patches of hyperfluorescence with 
irregular RPE detachments and relative hypofluorescence 
and large areas of irregular intense/intermediate choroidal 
hyperpermeability in all patients. OCT showed subclinical 
(,100 µm) or serous retinal detachment in all patients. Three 
patients (three eyes) had cystic changes as determined by OCT 
evaluations. Two patients (three eyes) had TTT involving the 
foveal area. Three eyes had two spots of TTT, three had one, 
and one had three. Four eyes of two patients with bilateral 
CCSC were treated in a paired manner (one eye had one spot 
of TTT, and three had two). Following treatment, there was 
complete resolution of subfoveal   neurosensory detachments 
and restoration of foveal anatomy on OCT in four of seven 
eyes at 1 month (Figure 1).
One eye showed a decrease in the height of the neu-
rosensory elevation, and two eyes did not show any sign 
of resolution. At months 3 and 6, the foveal detachment 
  completely resolved in three of the five patients,   corresponding 
to five of seven study eyes (P = ,0.001). Foveal detachment 
decreased but remained unresolved in one eye, and one eye 
did not show any sign of change (Figure 2).
Following treatment, there was a significant difference 
in VA at the 1-month, 3-month, and 6-month follow-up 
  compared with pretreatment. VA improved (P = ,0.001) 
by two or more lines in six eyes (four of five patients). 
In one eye, there was persisting serous elevation with no 
improvement in VA. No patient had a decrease in BCVA 
of three or more lines during the follow-up. One eye 
experienced   recurrent   macular detachment 6 months after 
  treatment, despite previous resolution of the detachment. 
After   treatment, no significant vascular effects were seen on 
FA or ICGA at initial examination, no dark zones or perfusion 
defects in the choriocapillaris were seen on FA and ICGA 
during the follow-up, and no RPE atrophy or retinal scars 
were observed in the area covered by the laser spot during 
the follow-up. No patient had any complications from the 
treatment. No foveal whitening was observed in any eye 
during or after TTT. No large foveal atrophy was present 
on angiographic or thickness studies.
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Figure 1 A) Fluorescein angiography (FA) shows multiple focal areas of hyperfluorescence with underlying retinal pigment epithelium (RPE) window defect involving the macula 
and the peripapillary region before transpupillary thermotherapy (TTT). B) Indocyanine green angiography (ICGA) showing multiple irregular patches of hyperfluorescence 
before TTT. Black circles indicate the area covered by large-spot subthreshold TTT. C) Optical coherence tomography (OCT) image of line scan through the macula showing 
macular neurosensory detachment with cystoid macular changes. D) FA showing slow, indistinct staining with absence of active focal leakage after TTT. E) iCGA showing 
choroidal patch of hyperfluorescence without significant vascular effects, dark zone, or perfusion defects in the choriocapillaris. OCT image showing resolution of the serous 
detachment and cystoid macular edema after treatment. F) No rPe atrophy or retinal scars were observed in the area covered by the laser spot during the follow-up.
Discussion
The primary tissue site effect and the cause of CCSC remain 
controversial. The natural course of the disease leads to 
  progressive deterioration in VA and visual field damage due 
to RPE and photoreceptor degeneration. Progressive atrophic 
degeneration of the RPE in a multizoned distribution evolves 
in both persistent and recurrent detachment, leading to chronic 
alteration of the posterior blood–retinal barrier. Some authors 
consider the RPE to be the site of   disturbance, with both 
focal and diffuse RPE cell impairment.26,27 For serous retinal 
detachment to form and be maintained, there must be an alter-
ation in the net balance of fluid flow into the   subretinal space. 
The RPE has a tremendous capacity to remove fluid from the 
subretinal space, and a focal leak in the RPE may produce a Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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serous retinal detachment. Several studies relying on ICGA 
have suggested that the etiology lies in the   choriocapillaris, 
with accumulation of exudates in the inner choroids,   leading 
to serous leakage beneath the   neurosensory retina and serous 
pigment   epithelium detachment formation.2,6,7,28 There is no 
standard   treatment for CCSC. Several reports have described 
focal laser   photocoagulation to treat subfoveal/juxtafoveal 
leakage as the first approach to chronic CSC.13,14 Although 
laser may shorten the duration of symptoms, it does not 
have any impact on final vision or on the   recurrence rate, 
with limited efficacy, because it is targeting only the RPE 
leak without specifically treating the underlying primary 
choroidal   congestion and hyperpermeability or the RPE 
  decompensation. PDT has recently been shown to have 
a   beneficial effect in patients with CCSC, displaying a 
  significant, rapid, short-term improvement in VA.15–17 
However, several side effects   occurring after PDT seem to 
be potentially   important   drawbacks in treating chronic CSC 
patients.18,19
In the present study, we adopted large-spot subthreshold 
TTT to apply a single treatment approach to the management 
of serous macula detachment in patients with CCSC. Five out 
of seven eyes (71%) displayed complete resolution of serous 
macular elevation, and VA improved by over two or more 
lines during follow-up in six eyes. In parallel with the VA 
data, there was also a statistically significant improvement 
in OCT-measured macular thickness at 6 months in six eyes 
(85%). The power setting was crucial for the successful 
treatment of TTT in our study. There is controversy about 
the clinical safety of TTT, limiting the possibility of applying 
an optimal dose of TTT. Clinical experience with TTT for 
CNV suggests that it is important to use subthreshold power 
(ie, biomicroscopically invisible laser effects) to avoid 
damaging the overlying neural retina, but the current treatment 
regimen remains largely empiric.30 In our study, the laser 
setting was determined by virtue of the fact that the   target 
tissue was nonproliferative choroids. The purpose of a 
  subthreshold power level was to avoid any associated damage 
to the RPE/choriocapillary complex. The spot size was 
dependent   primarily on the location and extent of choroidal 
hyperpermeability on ICGA. During long exposure with a 
large retinal spot, the power required to produce a particular 
rise in retinal temperature is proportional to the diameter rather 
than to the area of the spot on the retina.31 Conventional TTT 
  protocols recommend a power of 800 mW with a retinal spot 
of 3.0 mm, giving a power/diameter ratio of 247 mW/mm. 
We delivered a power/diameter ratio of 108 mW/mm, 
which is ≈40% of that used in conventional TTT for CNV . 
We believe that subthreshold TTT could be a viable method of 
selectively   confining the effect of laser on pigment epithelium, 
thus stimulating recovery of the outer blood–retinal barrier 
once the pump function has been regained. Conversely, this 
method may also have an impact on choroidal hyperperme-
ability, because retinochoroidal temperature elevation is also 
associated with heat shock protein (HSP) hyperexpression, 
producing a dual effect on the RPE/choroid complex.32,33 
The hypothesis is that confined, moderate subthreshold 
  thermal elevation at the level of the RPE/choroid complex 
may stimulate prompt repair of the RPE with HSP-induced 
cellular protection, in addition to reducing and accelerating 
functional recovery of choroidal cells.
Pigmentary changes, RPE mottling, or loss of transparency 
were not visible at ophthalmoscopy or during administration 
of FA and ICGA or throughout patient follow-up. We do agree 
that long-term follow-up is needed to examine maintenance 
of treatment gains and side effects. One of the seven eyes 
did not show any improvement in VA, revealing reduced/
persistent neurosensory detachment at OCT. Although we are 
unable to provide a clear explanation for this, the long-term 
duration of the disease may have a negative influence on 
retinal recovery due to atrophic changes in the outer retinal 
layer (outer plexiform layer and RPE) and the irreversible 
death of photoreceptors.
In conclusion, although this is a pilot study with several 
obvious limitations related to the inherent methodology in 
the study design, the lack of matched controls, the limited 
follow-up, and the number of patients, the treated eyes did 
show anatomic and functional improvements. This report 
is proof of the concept that TTT is at least effective in the 
short term in the treatment of serous detachment associated 
with CCSC.
Figure 2 The time course of the height of the foveal detachment in all study eyes. 
The height was measured by optical coherence tomography. in six cases, the foveal 
detachment decreased after transpupillary thermotherapy (TTT). The height was 
significantly lower at 3 and 6 months after treatment (P , 0.01).
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